Sökning: "klinisk farmakologi Uppsala"
Visar resultat 6 - 10 av 36 avhandlingar innehållade orden klinisk farmakologi Uppsala.
6. New Methods to Screen for Cancer Drugs and to Evaluate their Mechanism of Action
Sammanfattning : Cancer is a common disease and due to problems with resistance against cancer drugs and the limited benefit from chemotherapy in many diagnoses, there is a need to develop new cancer drugs. In this thesis new methods to screen for cancer drugs and to evaluate their mechanism of action are discussed. LÄS MER
7. Pharmacometric Models for Individualisation of Warfarin in Adults and Children
Sammanfattning : Warfarin is one of the most widely used anticoagulants. Therapy is complicated by warfarin’s narrow therapeutic range and pronounced variability in individual dose requirements. Although warfarin therapy is uncommon in children, it is crucial for children with certain congenital or acquired heart diseases. LÄS MER
8. Anticancer Activity of Melflufen : Preclinical Studies of a Novel Peptidase-Potentiated Alkylator
Sammanfattning : Melflufen (melphalan flufenamide, chemical name L-melphalanyl-p-L-fluorophenylalanine ethyl ester hydrochloride, previously called J1) is a derivative of the classical alkylating agent melphalan. Melflufen is potentiated by hydrolytic cleavage by aminopeptidase N (APN), leading to high intracellular concentrations of alkylating moieties and subsequent cell death. LÄS MER
9. Preclinical and Clinical Development of the Novel Cyanoguanidine CHS 828 for Cancer Treatment
Sammanfattning : CHS 828 is a cyanoguanidine with anti-tumour properties which has shown promising effects in several preclinical models. This thesis describes both preclinical and clinical studies aiming to investigate disease specific activity, clinical tolerability and efficacy of CHS 828. LÄS MER
10. Optimization of Colistin Dosage in the Treatment of Multiresistant Gram-negative Infections
Sammanfattning : As multidrug resistance in Gram-negative bacilli increases, the old antibiotic colistin has rapidly gained attention as one of few last line treatment options in the form of colistin methanesulfonate (CMS), which is hydrolyzed to colistin both in vitro and in vivo. There is a dearth of knowledge on fundamental aspects of colistin, including pharmacokinetics and optimal dosing regimens. LÄS MER
